AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-10 (Cancel).

11. (New) A method of promoting the healing of a wound or fibrotic disorder with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:

i) human IL-10,

ii) a fragment of human IL-10 that retains the anti-inflammatory healing functionality of human IL-10, and

iii) a partially modified form of human IL-10, or a fragment thereof, that has at least 60% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10,

sufficient to effect said promotion with reduced scarring.

12. (New) The method according to claim 11, wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

13. (New) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.

14. (New) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.

15. (New) The method according to claim 11, wherein the agent is administered to a wound site or site of a fibrotic disorder.

16. (New) The method according to claim 11, wherein the agent is administered at a concentration of between about 1μM and about 10μM.

17. (New) The method according to claim 16, wherein the agent is administered at a concentration of between about 2.5μM and about 5μM.

18. (New) The method according to claim 11 wherein said partially modified form of human IL-10, or fragment thereof, has at least 80% homology with IL-10.

19. (New) The method according to claim 18 wherein said partially modified form of human IL-10, or fragment thereof, has at least 95% homology with IL-10.